Harbour BioMed (HBM), a world scientific stage biopharmaceutical firm and Viva Biotech (Shanghai) Ltd. (“Viva Biotech”), a world-leading structure-based drug discovery platform in the present day introduced a strategic partnership underneath which each events will collate their respective experience in drug discovery and improvement to promote the incubation of revolutionary biotech startups.
HBM will mix its main Harbour Mice® platform H2L2 and its expertise in international analysis and improvement of revolutionary molecules, with Viva Biotech’s structure-based early stage drug discovery providers. This complementary partnership will supply revolutionary biotech startups entry to subsequent technology applied sciences that create synergies to speed up the trail between ideation to product. The incubated startups will function thorough scientific analysis and EFS (fairness for service) mannequin.
HBM has made vital progress since its institution in late-2016, by way of strategic collaborations and partnerships with main tutorial establishments and pharmaceutical and biotech firms internationally. The corporate has efficiently constructed a sturdy portfolio of early and late stage property in immune-oncology and immunology, by way of natural R&D in addition to in-licensing strategic property that tackle excessive unmet medical wants internationally. Its internally found subsequent technology ani-CTLA-Four antibody HBM4003 for strong tumors, primarily based on its HCAb platform is already in section 1 scientific trials.
Viva Biotech offers world-leading structure-based drug discovery providers to its biotechnology and pharmaceutical clients worldwide for his or her pre-clinical stage revolutionary drug improvement. The Group covers the complete spectrum of the purchasers’ wants for early stage drug discovery, together with organic goal protein expression and construction analysis, drug screening, lead optimization, and scientific candidate choice. The Group additionally offers discovery and incubation providers to biotechnology start-ups with excessive potential underneath its EFS (fairness for service) mannequin.
We’re excited to mix our capabilities with these of Viva Biotech’s to supply revolutionary startup firms’ entry to our subsequent technology know-how platforms and distinctive R&D capabilities. We’re at all times looking out for innovation that may positively impression human life, and this partnership will permit us to allow the interpretation of such concepts to merchandise which have international impression. Some of these revolutionary startups could grow to be the subsequent large biotech within the business. We glance ahead to supporting them in a number of methods, together with mentoring, alongside HBM’s and Viva Biotech’s administration groups.”
Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed
The strategic partnership between Viva Biotech and Harbour BioMed makes up for Viva Biotech’s deficiency in transgenic mouse platforms for producing totally human monoclonal antibodies, and will additional improve the scalability of Viva Biotech’s enterprise mannequin, thereby strengthening its potential in attracting and incubating extra revolutionary startups.”
Dr. Delin Ren, the president of Viva Biotech